Comparative Pharmacology
Head-to-head clinical analysis: NEO CORTEF versus NEO SYNALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORTEF versus NEO SYNALAR.
NEO-CORTEF vs NEO-SYNALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Neomycin (aminoglycoside) binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis. Fluocinolone acetonide (corticosteroid) binds to glucocorticoid receptor, inducing anti-inflammatory proteins and suppressing inflammatory mediators.
Apply a thin layer to the affected area 3 to 4 times daily. Use the 0.5% strength for mild conditions and 1% for more severe conditions.
Apply a thin layer to affected area twice daily. Maximum 60 g per week.
None Documented
None Documented
Terminal half-life 2-4 hours for neomycin; hydrocortisone half-life 1-2 hours. Clinical context: q6-8h dosing.
Approximately 2-4 hours for the corticosteroid component; clinical effect persists beyond due to cellular actions.
Renal (70-80% as free drug and metabolites), fecal (20-30% via bile).
Renal (primarily as metabolites): ~80%; biliary/fecal: ~20%.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic